Actions of Hims and his health Around 26% was closed on Friday after the United States drug and food administration announced that the scarcity of semaglutidal injection products has been resolved.
Semaglutida is the active ingredient in the weight loss of weight loss of novo nordisk and diabetes treatment. These medications are part of a medication class called LPG-1, and the demand for treatments has exploited in recent years. As a result, digital health companies such as Hims and Hers have prescribed the compounded semaglutida as an alternative for patients who are navigating volatile supply obstacles and insurance obstacles.
Composite medications are personalized alternatives to brand medications designed to meet the needs of a specific patient, and compounds can occur when brand name treatments are scarcity. FDA does not review the safety and effectiveness of compound products.
HIMS & HERS began to offer compound semaglutida to patients in May, and has compound pharmacies produced by medications.
Composite medications are usually much cheaper than their brand counterparts. HIMS & HERS sells semaglutida composed of less than $ 200 per month, while Ozempic and Wogovy cost around $ 1,000 per month without insurance.
The FDA said Friday that it will begin to take measures against the compounds of violations in the next 60 to 90 days, depending on the type of installation, to “avoid unnecessary interruption for patient treatment.”
“Now that the FDA has determined that the shortage of drugs for the semaglutida has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet the needs of patients,” the CEO of Hims & Hers the CEO published on Friday Friday in X. Also monitoring closely the possible future shortage, as Novo Nordisk declared two weeks ago that he would continue to have 'capacity limitations' and' limitations of expected continuous periodic supply and related notifications of medication scarcity '”.
The weight loss offerings of him and it have been a great success with investors. The company's shares rose more than 200% last year, and the action has already increased more than 100% this year despite Friday's move.
Even before adding the GLP-1 compounds to its portfolio, the company said in its profit-quarter-quarterly gain call that it expects its weight loss program to generate more than $ 100 million in revenues by the end of 2025.
Despite the turbulent regulatory landscape, Hims & Hers has not shown signs of deceleration.
On Friday, the company announced that it has acquired an installation of headquarters in the United States that “will further verticalize the company's long -term capacity to deliver custom medications.” HIMS & HERS will explore advances through metabolic optimization, recovery science, biological resistances, cognitive performance and preventive health through acquisition, said the company.
That movement occurs only a few days after HIMS and Hers also bought Trybe Labs, the installation of laboratory tests at the home based in New Jersey. Trybe Labs will allow him and hers to make blood raffles at the home and more complete pretreatment tests.
Hims & Hers did not reveal the terms of any of the treatment.
LOOK: Hims and his Super Bowl Ad Chemills Controversy
